JP2002500198A - 脱感作のための方法及び組成物 - Google Patents
脱感作のための方法及び組成物Info
- Publication number
- JP2002500198A JP2002500198A JP2000527273A JP2000527273A JP2002500198A JP 2002500198 A JP2002500198 A JP 2002500198A JP 2000527273 A JP2000527273 A JP 2000527273A JP 2000527273 A JP2000527273 A JP 2000527273A JP 2002500198 A JP2002500198 A JP 2002500198A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- allergen
- mhc class
- patient
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 104
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 238000000586 desensitisation Methods 0.000 title description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 456
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 192
- 239000013566 allergen Substances 0.000 claims abstract description 180
- 230000004044 response Effects 0.000 claims abstract description 70
- 108091054438 MHC class II family Proteins 0.000 claims abstract description 69
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 66
- 102000043131 MHC class II family Human genes 0.000 claims abstract description 63
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 61
- 229920001184 polypeptide Polymers 0.000 claims abstract description 49
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 19
- 230000001024 immunotherapeutic effect Effects 0.000 claims abstract description 10
- 208000030961 allergic reaction Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 59
- 241000282326 Felis catus Species 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 22
- 230000006052 T cell proliferation Effects 0.000 claims description 19
- 230000001747 exhibiting effect Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000001516 cell proliferation assay Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241001674044 Blattodea Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 241000254173 Coleoptera Species 0.000 claims description 3
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims description 3
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 claims description 3
- 241000255925 Diptera Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000238876 Acari Species 0.000 claims description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 claims description 2
- 241000256844 Apis mellifera Species 0.000 claims description 2
- 241000239290 Araneae Species 0.000 claims description 2
- 241000255789 Bombyx mori Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 241000700198 Cavia Species 0.000 claims description 2
- 241000254171 Curculionidae Species 0.000 claims description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000699694 Gerbillinae Species 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 241000736227 Lucilia sericata Species 0.000 claims description 2
- 102000043129 MHC class I family Human genes 0.000 claims description 2
- 108091054437 MHC class I family Proteins 0.000 claims description 2
- 241000257226 Muscidae Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 235000003484 annual ragweed Nutrition 0.000 claims description 2
- 235000006263 bur ragweed Nutrition 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 235000003488 common ragweed Nutrition 0.000 claims description 2
- 235000009736 ragweed Nutrition 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 244000036975 Ambrosia artemisiifolia Species 0.000 claims 1
- 241000202814 Cochliomyia hominivorax Species 0.000 claims 1
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 1
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 1
- 101710204040 Myosin-3 Proteins 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 76
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 75
- 210000001744 T-lymphocyte Anatomy 0.000 description 70
- 229960004784 allergens Drugs 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 34
- 208000006673 asthma Diseases 0.000 description 28
- 239000007924 injection Substances 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 17
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 17
- 208000026935 allergic disease Diseases 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 208000010668 atopic eczema Diseases 0.000 description 13
- 230000000172 allergic effect Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004209 hair Anatomy 0.000 description 11
- 230000006044 T cell activation Effects 0.000 description 10
- 230000007815 allergy Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 229940074608 allergen extract Drugs 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 102100039897 Interleukin-5 Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940032238 cat hair extract Drugs 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 231100000430 skin reaction Toxicity 0.000 description 6
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 5
- 241000218645 Cedrus Species 0.000 description 5
- 206010040914 Skin reaction Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000035483 skin reaction Effects 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 108700005092 MHC Class II Genes Proteins 0.000 description 4
- 108010066345 MHC binding peptide Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 229940127558 rescue medication Drugs 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 208000003926 Myelitis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000238739 Euroglyphus Species 0.000 description 2
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 2
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 2
- 108700037339 HLA-DR13 antigen Proteins 0.000 description 2
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102400000401 Latency-associated peptide Human genes 0.000 description 2
- 241000209082 Lolium Species 0.000 description 2
- 241000997826 Melanocetus johnsonii Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 240000006694 Stellaria media Species 0.000 description 2
- 241000256838 Vespula Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- -1 sulfide leukotrienes Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 101100243820 Caenorhabditis elegans phlp-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
- 241000726768 Carpinus Species 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- 241000983417 Chrysomya bezziana Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 1
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 1
- 108010082996 Dermatophagoides farinae antigen f 4 Proteins 0.000 description 1
- 108010082990 Dermatophagoides farinae antigen f 7 Proteins 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 108010061612 Dermatophagoides pteronyssinus antigen p 3 Proteins 0.000 description 1
- 108010061569 Dermatophagoides pteronyssinus antigen p 4 Proteins 0.000 description 1
- 108010061573 Dermatophagoides pteronyssinus antigen p 5 Proteins 0.000 description 1
- 108010061636 Dermatophagoides pteronyssinus antigen p 6 Proteins 0.000 description 1
- 108010061638 Dermatophagoides pteronyssinus antigen p 7 Proteins 0.000 description 1
- 108700013752 Felis domesticus Fel d 1 Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
- 101000725943 Homo sapiens RNA polymerase II subunit A C-terminal domain phosphatase Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025912 Melanopsin Human genes 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 101000590737 Poa pratensis Pollen allergen KBG 31 Proteins 0.000 description 1
- 101000590736 Poa pratensis Pollen allergen KBG 41 Proteins 0.000 description 1
- 101000590741 Poa pratensis Pollen allergen KBG 60 Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 102100027669 RNA polymerase II subunit A C-terminal domain phosphatase Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010004321 allergen Ves v 1 Proteins 0.000 description 1
- 108010004452 allergen Ves v 2 Proteins 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013213 metal-organic polyhedra Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000012011 method of payment Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9800445.0 | 1998-01-09 | ||
| GBGB9800445.0A GB9800445D0 (en) | 1998-01-09 | 1998-01-09 | Method for desensitisation |
| GB9820474.6 | 1998-09-21 | ||
| GBGB9820474.6A GB9820474D0 (en) | 1998-09-21 | 1998-09-21 | Method for desensitisation |
| PCT/GB1999/000080 WO1999034826A1 (en) | 1998-01-09 | 1999-01-11 | Methods and compositions for desensitisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500198A true JP2002500198A (ja) | 2002-01-08 |
| JP2002500198A5 JP2002500198A5 (cg-RX-API-DMAC7.html) | 2009-11-05 |
Family
ID=26312916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527273A Pending JP2002500198A (ja) | 1998-01-09 | 1999-01-11 | 脱感作のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040265342A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1044019A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002500198A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2064899A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2317724A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2348808B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999034826A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006516382A (ja) * | 2002-08-19 | 2006-07-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | オオアワガエリからの主要アレルゲンＰｈｌｐ１の変異体 |
| JP2009532361A (ja) * | 2006-03-30 | 2009-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉｇｅを標的としたｄｎａワクチン接種 |
| JP2010529836A (ja) * | 2007-06-01 | 2010-09-02 | サーカッシア リミテッド | 猫アレルギーに対するワクチンペプチド併用剤 |
| JP2012510457A (ja) * | 2008-11-28 | 2012-05-10 | サーカッシア リミテッド | 二量体形成の減少した組成物 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69940805D1 (de) | 1998-01-31 | 2009-06-10 | Sinai School Medicine | Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie |
| AUPQ884500A0 (en) * | 2000-07-18 | 2000-08-10 | National University Of Singapore, The | Novel therapeutic molecules and uses therefor - III |
| US6572859B1 (en) | 1999-10-29 | 2003-06-03 | Pharmacia Diagnostics Ab | Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use |
| EP2258852A1 (en) * | 2000-04-28 | 2010-12-08 | Novozymes A/S | Lipolytic enzyme variant |
| IT1318690B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti dell'allergene maggiore par j 2 di parietaria judaica. |
| FR2824326B1 (fr) * | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
| AUPR779201A0 (en) * | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| DE60229979D1 (cg-RX-API-DMAC7.html) * | 2001-12-05 | 2009-01-02 | Circassia Ltd | |
| SE0200946D0 (sv) * | 2002-03-27 | 2002-03-27 | Pharmacia Diagnostics Ab | Novel Allergen |
| EP1403280B1 (en) * | 2002-09-27 | 2005-08-31 | BIOMAY Produktions- und Handels- Aktiengesellschaft | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7 |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| EP1958645A1 (en) * | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| AU2013202871B2 (en) * | 2007-06-01 | 2015-10-22 | Circassia Limited | Vaccine peptide combinations against cat allergy |
| WO2009022155A2 (en) | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with reduced dimer formation |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| DK2153841T4 (en) | 2008-08-15 | 2016-02-15 | Circassia Ltd | Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| AU2015227499B2 (en) * | 2008-11-28 | 2017-06-22 | Circassia Limited | Compositions with reduced dimer formation |
| BRPI1008802A2 (pt) | 2009-02-05 | 2016-03-08 | Circassia Ltd | composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição |
| WO2011085783A1 (de) * | 2010-01-14 | 2011-07-21 | Merck Patent Gmbh | VARIANTEN DER GRUPPE 5-ALLERGENE DER SÜßGRÄSER MIT REDUZIERTER ALLERGENITÄT DURCH MUTAGENESE VON PROLINRESTEN |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| CN118078979A (zh) | 2011-04-29 | 2024-05-28 | 西莱克塔生物科技公司 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
| US11421006B2 (en) | 2012-05-03 | 2022-08-23 | La Jolla Institute For Allergy And Immunology | T cell epitopes from Cockroach and methods of making and using same |
| DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
| US10434088B2 (en) | 2013-05-03 | 2019-10-08 | Selecta Biosciences, Inc. | Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose |
| JP7007534B2 (ja) | 2013-09-25 | 2022-01-24 | アラヴァックス ピーティーワイ リミテッド | 新規免疫療法組成物およびその使用 |
| WO2016037165A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses |
| CN108265057B (zh) * | 2016-12-31 | 2019-10-18 | 江苏众红生物工程创药研究院有限公司 | 一种重组户尘螨2类变应原蛋白及其制备方法和应用 |
| CN108265059B (zh) * | 2016-12-31 | 2021-01-05 | 江苏众红生物工程创药研究院有限公司 | 一种重组粉尘螨2类变应原蛋白及其制备方法与应用 |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4163778A (en) * | 1978-05-04 | 1979-08-07 | The Foundation for the Study of Asthma and Related Diseases | Asthma immunotherapy |
| US4338297A (en) * | 1980-02-19 | 1982-07-06 | Michael Jacob G | Polypeptide active pollen immunosuppressant fraction |
| US6180368B1 (en) * | 1988-03-23 | 2001-01-30 | University Of Melbourne | Ryegrass pollen allergen |
| US5547669A (en) * | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| US6019972A (en) * | 1989-11-03 | 2000-02-01 | Immulogic Pharmaceutical Corporation | Peptides of human T cell reactive feline protein (TRFP) |
| WO1992011859A1 (en) * | 1991-01-08 | 1992-07-23 | Immulogic Pharmaceutical Corporation | Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) |
| FR2715538B1 (fr) * | 1994-02-01 | 1996-04-26 | Roquette Freres | Composition de chewing-gum présentant une qualité organoleptique améliorée et procédé permettant de préparer un tel chewing-gum. |
| AU2238395A (en) * | 1994-04-01 | 1995-10-23 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
| EP0923940B1 (en) * | 1996-03-10 | 2008-09-03 | Meiji Dairies Corporation | Peptide-based immunotherapeutic agent for allergic diseases |
| US5804201A (en) * | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
-
1999
- 1999-01-11 EP EP99901014A patent/EP1044019A1/en not_active Withdrawn
- 1999-01-11 CA CA002317724A patent/CA2317724A1/en not_active Abandoned
- 1999-01-11 GB GB0016438A patent/GB2348808B/en not_active Expired - Fee Related
- 1999-01-11 JP JP2000527273A patent/JP2002500198A/ja active Pending
- 1999-01-11 AU AU20648/99A patent/AU2064899A/en not_active Abandoned
- 1999-01-11 WO PCT/GB1999/000080 patent/WO1999034826A1/en not_active Ceased
-
2004
- 2004-03-25 US US10/809,689 patent/US20040265342A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| JPN6009007296, ＴＡＫＡＩ， Ｔ．， ｅｔ ａｌ．, "Ｅｎｇｉｎｅｅｒｉｎｇ ｏｆ ｔｈｅ ｍａｊｏｒ ｈｏｕｓｅ ｄｕｓｔ ｍｉｔｅ ａｌｌｅｒｇｅｎ Ｄｅｒ ｆ ２ ｆｏｒ ａｌｌｅｒｇｅｎ−ｓｐｅｃｉｆｉｃ ｉｍｍｕｎｏｔｈｅｒａｐｙ", ＮＡＴＵＲＥ ＢＩＯＴＥＣＨＮＯＬＯＧＹ, 199708, Ｖｏｌ．１５， Ｎｏ．８, ｐ．７５４−７５８ * |
| JPN6009007297, 奥村 康， 他．, "リコンビナントダニ抗原", 感染・炎症・免疫, 199712, Ｖｏｌ．２７， Ｎｏ．４, ｐ．２５６−２５８, JP * |
| JPN6009007299, メルク マニュアル 第１６版, 19950501, 日本語版第１版第３刷, ｐ．３１１ * |
| JPN6009007300, 奥平博一， 他．, "Ｔ細胞アナジーと経口減感作療法", 医学のあゆみ, 19950513, Ｖｏｌ．１７３， Ｎｏ．７, ｐ．６４７−６４９ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006516382A (ja) * | 2002-08-19 | 2006-07-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | オオアワガエリからの主要アレルゲンＰｈｌｐ１の変異体 |
| JP2011097940A (ja) * | 2002-08-19 | 2011-05-19 | Merck Patent Gmbh | オオアワガエリからの主要アレルゲンＰｈｌｐ１の変異体 |
| JP2009532361A (ja) * | 2006-03-30 | 2009-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉｇｅを標的としたｄｎａワクチン接種 |
| JP2010529836A (ja) * | 2007-06-01 | 2010-09-02 | サーカッシア リミテッド | 猫アレルギーに対するワクチンペプチド併用剤 |
| JP2013256507A (ja) * | 2007-06-01 | 2013-12-26 | Circassia Ltd | 猫アレルギーに対するワクチンペプチド併用剤 |
| JP2012510457A (ja) * | 2008-11-28 | 2012-05-10 | サーカッシア リミテッド | 二量体形成の減少した組成物 |
| JP2015057383A (ja) * | 2008-11-28 | 2015-03-26 | サーカッシア リミテッド | 二量体形成の減少した組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1044019A1 (en) | 2000-10-18 |
| AU2064899A (en) | 1999-07-26 |
| GB0016438D0 (en) | 2000-08-23 |
| WO1999034826A1 (en) | 1999-07-15 |
| GB2348808A (en) | 2000-10-18 |
| CA2317724A1 (en) | 1999-07-15 |
| US20040265342A1 (en) | 2004-12-30 |
| GB2348808B (en) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002500198A (ja) | 脱感作のための方法及び組成物 | |
| JP6040207B2 (ja) | アレルゲンに対する脱感作のためのペプチド | |
| Stromnes et al. | Active induction of experimental allergic encephalomyelitis | |
| JP5788319B2 (ja) | ブタクサアレルギーの治療用のＡｍｂａ１ペプチド | |
| JP3732231B2 (ja) | アレルギー疾患に対するペプチド免疫療法剤 | |
| JPH05507911A (ja) | 多発性硬化症ｔ細胞受容体 | |
| US7595052B2 (en) | Composition and method for the prevention and/or the treatment of allergy | |
| JPWO1997032600A1 (ja) | アレルギー疾患に対するペプチド免疫療法剤 | |
| AU2011333756B2 (en) | Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells | |
| AU2001243964A1 (en) | Composition and method for the prevention and/or the treatment of allergy | |
| KR100540417B1 (ko) | 펩티드 면역 요법 치료제 | |
| CN105120894A (zh) | 新颖的免疫治疗分子和其用途 | |
| Barry Kay et al. | Allergen immunotherapy with cat allergen peptides | |
| JP4340329B2 (ja) | 潜在ペプチドならびにそれらの同定方法 | |
| CZ63297A3 (en) | Peptide preparations capable of attenuating antigen specific immune response | |
| AU2003203987B2 (en) | Methods and compositions for desensitisation | |
| JP4085092B2 (ja) | アレルギー疾患に対するペプチド免疫療法剤 | |
| US20240285732A1 (en) | Patient Profiling for Antigen-Specific Immunomodulatory Therapies | |
| Mohapatra et al. | Application of molecular biology for diagnosis and treatment of allergic diseases | |
| Wang | From Allergen Extracts to Allergen Genes and Allergen Molecules | |
| Larché et al. | The effects of T cell peptides in patients sensitive to cats | |
| Canonica | Allergen immunotherapy: therapeutic vaccines for allergic diseases | |
| Kenner et al. | Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice | |
| JP2005336204A (ja) | アレルギー疾患に対するペプチド免疫療法剤 | |
| BG63183B2 (bg) | Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090310 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090609 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090610 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090616 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090617 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090908 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101019 |